Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly Reuters
Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly - Reuters
In short
Novo Nordisk’s oral version of its Wegovy weight-loss drug has outperformed forecasts. The performance comes as the company continues to battle competitor Eli Lilly in the pharmaceutical market.
Key points
- Novo Nordisk’s oral version of its Wegovy weight-loss drug has outperformed forecasts.: Novo Nordisk’s oral version of its Wegovy weight-loss drug has outperformed forecasts.
- The performance comes as the company continues to battle competitor Eli Lilly in the phar…: The performance comes as the company continues to battle competitor Eli Lilly in the pharmaceutical market.